---
title: "Immuneering Corp 1Q 2026: Revenue ($13.78M), Net income ($13.46M), EPS ($0.21) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286561646.md"
description: "Immuneering Corp reported Q1 2026 results with revenue of $13.78M and a net income of $13.46M, showing improvements from the previous year. The company initiated Phase 3 trials for atebimetinib in pancreatic cancer and shifted focus from envometinib, cutting its spending significantly. Cash resources are projected to support operations until 2029."
datetime: "2026-05-15T12:01:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286561646.md)
  - [en](https://longbridge.com/en/news/286561646.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286561646.md)
---

# Immuneering Corp 1Q 2026: Revenue ($13.78M), Net income ($13.46M), EPS ($0.21) — 10-Q Summary

Immuneering Corp reported first-quarter 2026 results showing a narrower comprehensive loss versus the prior year, with comprehensive loss of ($13.78M) and net loss of ($13.46M), or ($0.21) per diluted share.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

($13.78M)

($15.05M)

8.4%

Net income²

($13.46M)

($15.05M)

10.5%

Diluted EPS³

($0.21)

($0.42)

50%

_¹ Reported as “Comprehensive Loss”. ² Reported as “Net loss”. ³ Reported as “loss per share attributable to common stockholders, basic and diluted”._

**Business Highlights**

-   Clinical progress: Initiated Phase 3 MAPKeeper 301 for atebimetinib in first-line metastatic pancreatic ductal adenocarcinoma (PDAC); first patient dosing expected mid‑2026.
-   Pipeline focus shift: Company prioritized atebimetinib over envometinib and cut envometinib spending by roughly 99% to reallocate resources.
-   Data & differentiation: Positive Phase 2a interim safety/response and ctDNA data support the DCI hypothesis and potential reduced resistance.
-   Operational capacity: Integrated BioArkive to support internal preclinical work, expanded R&D headcount and increased preclinical spending.
-   Funding runway: Cash resources are expected to fund operations into 2029, supporting ongoing clinical advancement and trial execution.

Original SEC Filing: Immuneering Corp \[ IMRX \] - 10-Q - May. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [IMRX.US](https://longbridge.com/en/quote/IMRX.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)
- [Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference](https://longbridge.com/en/news/286652404.md)
- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)
- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)